MarketPulse

COPD

3 articles
GlobeNewswire Inc.GlobeNewswire Inc.··Upstream Bio, Inc.

Upstream Bio to Unveil Extended VIBRANT Trial Data on Verekitug at AAAAI 2026

Upstream Bio will present expanded VIBRANT trial data on verekitug for chronic rhinosinusitis with nasal polyps at AAAAI 2026, including new efficacy analyses accounting for rescue therapy use.
UPBPhase 2 clinical trialmonoclonal antibody
The Motley FoolThe Motley Fool··Jonathan Ponciano

Great Point Partners Doubles Down on Apogee Therapeutics With $28M Position

Great Point Partners expands Apogee Therapeutics stake to $28.23M, now its largest holding. Stock doubled in value; Phase 2 atopic dermatitis data expected mid-2026.
APGEbiotechclinical trials
GlobeNewswire Inc.GlobeNewswire Inc.··Not Specified

Upstream Bio to Present Pipeline Progress at Major Healthcare Conferences

Upstream Bio will present pipeline progress at two March 2026 healthcare conferences, discussing its TSLP receptor antagonist in Phase 2 trials for severe respiratory conditions.
UPBinvestor conferenceverekitug